Antipodes Partners’s Biogen BIIB Stock Holding History

Antipodes Partners’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$18.8M	Buy	+86,827	New	+$16.6M	0.34%	57

Other funds holding BIIB

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Antipodes Partners's BIIB Position: Q2 2026 in Review

Antipodes Partners opened a new position in Biogen (BIIB) in Q2 2026: 86,827 shares worth $18.8M. The stake represents 0.34% of the portfolio and ranks #57 among its holdings.

1,036 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.

Antipodes Partners held 86,827 shares of Biogen worth $18.8M as of Q2 2026.
Biogen was a new Antipodes Partners position in Q2 2026.
Biogen made up 0.34% of Antipodes Partners's portfolio in Q2 2026, its #57 holding.
1,036 funds tracked by Wall St. Rank held Biogen as of Q2 2026.

Based on Antipodes Partners's 13F filing for Q2 2026, filed 6 Aug 2026.